Melanoma pp 1-13 | Cite as

History of Melanoma

  • John F. ThompsonEmail author
  • Richard Kefford
  • Graham Stevens
  • Richard Scolyer


Until the mid-twentieth century, the clinical and pathological features of melanoma were not well documented, prognostic factors were poorly understood, and the evidence base for management strategies was sadly deficient. Aggressive treatment approaches for both the primary melanoma site and the regional lymph nodes had been established by the early 1900s, and continuing as the standard of care until the early 1980s. Several clinical trials failed to demonstrate a survival benefit for patients having a very wide excision of their primary melanoma, or those having elective lymph node dissection (ELND), although in two of the largest studies there was a trend in favor of ELND. In 1992, Morton et al. reported the technique of sentinel node biopsy (SNB). This identified node-positive patients most likely to benefit from a completion lymph node dissection (CLND). A large international trial, MSLT-I, showed no overall survival benefit for SNB, but did show a substantial survival benefit for SN-positive patients treated by immediate CLND compared to patients whose regional nodes were simply observed, and treated by CLND only if nodal metastases later became apparent. Initial results of a second trial initiated by Morton, MSLT-II, indicate that routine CLND in SN-positive patients confers no additional survival benefit. In the last decade, targeted inhibitors of the MAP kinase pathway and immune checkpoint inhibitors have produced remarkable improvements in the previously dismal survival outcome for patients with systemic melanoma metastases. Furthermore, the role of these agents as neoadjuvant and adjuvant therapies in high-risk patients is currently being assessed.


Melanoma History Treatment Surgery Radiotherapy Medical oncology 


  1. 1.
    Rebecca VW, Sondak VK, Smalley KS. A brief history of melanoma: from mummies to mutations. Melanoma Res. 2012;22:114–22.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Rotte A, Bhandaru M. Melanoma—introduction, history and epidemiology. Immunotherapy of melanoma. Cham: Springer International Publishing AG; 2016. p. 3–20.Google Scholar
  3. 3.
    Laennec RTH. Extrait au memoire de M Laennec, sur les melanoses. Paris: Bull L’Ecole Societie de Medicine; 1812; p. 24.Google Scholar
  4. 4.
    Gorantla VC, Kirkwood JM. State of melanoma: an historic overview of a field in transition. Hematol Oncol Clin North Am. 2014;28:415–35.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Urteaga O, Pack GT. On the antiquity of melanoma. Cancer. 1966;19:607–10.CrossRefPubMedGoogle Scholar
  6. 6.
    McGovern VJ. Melanoblastoma. Med J Aust. 1952;1:139–42.PubMedGoogle Scholar
  7. 7.
    Paget J. Lectures on surgical pathology. In: Turner W, editor. London: Longman, Brown, Green and Longman; 1853. p. 639.Google Scholar
  8. 8.
    Moles and malignant melanoma: terminology and classification. Med J Aust. 1967;1:123–5.Google Scholar
  9. 9.
    de Vries E, Bray F, Coebergh JW, et al. Melanocytic tumours. In: PE LB, Burg G, Weedon D, Sarasin A, editors. World Health Organisation classification of tumours: pathology and genetics of skin tumours. Lyon: International Agency for Research on Cancer (IARC) Press; 2006. p. 49–120.Google Scholar
  10. 10.
    Clark WH Jr, From L, Bernardino EA, et al. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res. 1969;29:705–27.PubMedPubMedCentralGoogle Scholar
  11. 11.
    McGovern VJ. The classification of melanoma and its relationship with prognosis. Pathology. 1970;2:85–98.CrossRefPubMedGoogle Scholar
  12. 12.
    Mihm MC Jr, Clark WH Jr, From L. The clinical diagnosis, classification and histogenetic concepts of the early stages of cutaneous malignant melanomas. N Engl J Med. 1971;284:1078–82.CrossRefPubMedGoogle Scholar
  13. 13.
    Allen AC, Spitz S. Malignant melanoma; a clinicopathological analysis of the criteria for diagnosis and prognosis. Cancer. 1953;6:1–45.CrossRefPubMedGoogle Scholar
  14. 14.
    Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg. 1970;172:902–8.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Gershenwald JE, Scolyer RA, Hess KR, et al. for members of the American Joint Committee on Cancer Melanoma Expert P, the International Melanoma D, Discovery P. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017;67:472–492Google Scholar
  16. 16.
    McGovern VJ, Mihm MC Jr, Bailly C, et al. The classification of malignant melanoma and its histologic reporting. Cancer. 1973;32:1446–57.CrossRefPubMedGoogle Scholar
  17. 17.
    Arrington JH 3rd, Reed RJ, Ichinose H, et al. Plantar lentiginous melanoma: a distinctive variant of human cutaneous malignant melanoma. Am J Surg Pathol. 1977;1:131–43.CrossRefPubMedGoogle Scholar
  18. 18.
    McGovern VJ, Cochran AJ, Van der Esch EP, et al. The classification of malignant melanoma, its histological reporting and registration: a revision of the 1972 Sydney classification. Pathology. 1986;18:12–21.CrossRefPubMedGoogle Scholar
  19. 19.
    Bahmer FA, Bahmer JA. Cutaneous melanoma—“black death” of modern times? Traces in contemporary literature. Hautarzt. 2013;64:864–7.CrossRefPubMedGoogle Scholar
  20. 20.
    Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma in the era of molecular profiling. Lancet. 2009;374:362–5.CrossRefPubMedGoogle Scholar
  21. 21.
    Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353:2135–47.CrossRefGoogle Scholar
  22. 22.
    Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell. 2015;161:1681–96.Google Scholar
  23. 23.
    Norris W. Eight cases of melanosis with pathological and therapeutic remarks on that disease. London: Longman and Robarts; 1857.Google Scholar
  24. 24.
    Norris W. Case of fungoid disease. Edinburgh Med Surg J. 1820;16:562–5.Google Scholar
  25. 25.
    Begg CB, Orlow I, Hummer AJ, et al. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample. J Natl Cancer Inst. 2005;97:1507–15.CrossRefPubMedGoogle Scholar
  26. 26.
    Pemberton O. On melanosis. Observations on the history, pathology and treatment of cancerous disease. London: John Churchill; 1858. p. 1–38.Google Scholar
  27. 27.
    Davis NC, Shaw HM, McCarthy WH. Melanoma: an historical perspective. In: Thompson JF, Morton DL, Kroon BBR, editors. Textbook of melanoma. London, UK: Martin Dunitz; 2004. p. 1–12.Google Scholar
  28. 28.
    Randle HW. Suntanning: differences in perceptions throughout history. Mayo Clin Proc. 1997;72:461–6.CrossRefPubMedGoogle Scholar
  29. 29.
    Lancaster HO. Some geographical aspects of the mortality from melanoma in Europeans. Med J Aust. 1956;43:1082–7.PubMedGoogle Scholar
  30. 30.
    Cooper AGS. The contribution of radiotherapy to the problem of skin cancer in Queensland. Acta Radiol Suppl. 1959;188:61–70.PubMedGoogle Scholar
  31. 31.
    Sarnat BG, Schour I. Oral and facial cancer. Chicago: The Yearbook Publishers, Inc.; 1950.Google Scholar
  32. 32.
    Lancaster HO, Nelson J. Sunlight as a cause of melanoma; a clinical survey. Med J Aust. 1957;44:452–6.PubMedGoogle Scholar
  33. 33.
    Cooper S. The first lines of the theory and practice of surgery. London: Longman; 1840.Google Scholar
  34. 34.
    Home E. Observations on cancer, connected with histories of the disease. London: W. Bulmer and Co.; 1805.Google Scholar
  35. 35.
    Bodenham DC. A study of 650 observed malignant melanomas in the south-west region. Ann R Coll Surg Engl. 1968;43:218–39.PubMedPubMedCentralGoogle Scholar
  36. 36.
    Fergusson A. Recurrence of a melanotic tumour: removal. Lancet. 1851;57:622.CrossRefGoogle Scholar
  37. 37.
    McCarthy WH, Shaw HM. The surgical treatment of primary melanoma. Hematol Oncol Clin North Am. 1998;12:797–805. CrossRefPubMedGoogle Scholar
  38. 38.
    Snow H. Melanotic cancerous disease. Lancet. 1892;140:872–4.CrossRefGoogle Scholar
  39. 39.
    Eve F. A lecture on melanoma. Practitioner. 1903;70:165–74.Google Scholar
  40. 40.
    Handley WS. The pathology of melanotic growths in relation to their operative treatment. Lancet. 1907;169:927–33.CrossRefGoogle Scholar
  41. 41.
    Pringle JH. A method of operation in melanotic tumours of the skin. Edinb Med J. 1908;23:496–9.PubMedCentralGoogle Scholar
  42. 42.
    Balch CM, Soong S, Ross MI, et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol. 2000;7:87–97.CrossRefPubMedGoogle Scholar
  43. 43.
    Cascinelli N, Morabito A, Santinami M, et al. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme. Lancet. 1998;351:793–6.CrossRefPubMedGoogle Scholar
  44. 44.
    Röntgen WC, Stokes GGB, Thomson JJ. Röntgen rays—memoirs by Röntgen, Stokes and JJ Thomson. New York and London: Harper & Brothers Publishers; 1899.Google Scholar
  45. 45.
    Becquerel H. Sur les radiations émises par phosphorescence. C R Acad Sci. 1896;122:420–1.Google Scholar
  46. 46.
    Curie P, Curie M, Bémont MG. Sur une nouvelle substance fortement redio-active, contenue dans la pecheblende. C R Acad Sci. 1898;127:1215–7.Google Scholar
  47. 47.
    Coutard H. The results and methods of treatment of cancer by radiation. Ann Surg. 1937;106:584–98.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Dewey DL. The radiosensitivity of melanoma cells in culture. Br J Radiol. 1971;44:816–7.CrossRefPubMedGoogle Scholar
  49. 49.
    Barranco SC, Romsdahl MM, Humphrey RM. The radiation response of human malignant melanoma cells grown in vitro. Cancer Res. 1971;31:830–3.PubMedGoogle Scholar
  50. 50.
    Johanson CR, Harwood AR, Cummings BJ, et al. 0-7-21 radiotherapy in nodular melanoma. Cancer. 1983;51:226–32.CrossRefPubMedGoogle Scholar
  51. 51.
    Burmeister BH, Henderson MA, Ainslie J, et al. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol. 2012;13:589–97.CrossRefPubMedGoogle Scholar
  52. 52.
    Overgaard J, Gonzalez Gonzalez D, Hulshof MC, et al. Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre randomized trial by the European Society for Hyperthermic Oncology. Int J Hyperth. 1996;12:3–20.CrossRefGoogle Scholar
  53. 53.
    Larsson BS, Larsson B, Roberto A. Boron neutron capture therapy for malignant melanoma: an experimental approach. Pigment Cell Res. 1989;2:356–60.CrossRefPubMedGoogle Scholar
  54. 54.
    Raja C, Graham P, Abbas Rizvi SM, et al. Interim analysis of toxicity and response in phase 1 trial of systemic targeted alpha therapy for metastatic melanoma. Cancer Biol Ther. 2007;6:846–52.CrossRefPubMedGoogle Scholar
  55. 55.
    Lawton AW. Proton beam therapy for uveal melanoma. Ophthalmology. 1989;96:138–9.CrossRefPubMedGoogle Scholar
  56. 56.
    Marucci L, Ancukiewicz M, Lane AM, et al. Uveal melanoma recurrence after fractionated proton beam therapy: comparison of survival in patients treated with reirradiation or with enucleation. Int J Radiat Oncol Biol Phys. 2011;79:842–6.CrossRefPubMedGoogle Scholar
  57. 57.
    Yaeh A, Nanda T, Jani A, et al. Control of brain metastases from radioresistant tumors treated by stereotactic radiosurgery. J Neuro-Oncol. 2015;124:507–14.CrossRefGoogle Scholar
  58. 58.
    Okwan-Duodu D, Pollack BP, Lawson D, et al. Role of radiation therapy as immune activator in the era of modern immunotherapy for metastatic malignant melanoma. Am J Clin Oncol. 2015;38:119–25.CrossRefPubMedGoogle Scholar
  59. 59.
    Creech O Jr, Krementz ET, Ryan RF, et al. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg. 1958;148:616–32.CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Kapma MR, Vrouenraets BC, Nieweg OE, et al. Major amputation for intractable extremity melanoma after failure of isolated limb perfusion. Eur J Surg Oncol. 2005;31:95–9.CrossRefPubMedGoogle Scholar
  61. 61.
    Thompson JF, Waugh RC, Saw RPM, et al. Isolated limb infusion with melphalan for recurrent limb melanoma: a simple alternative to isolated limb perfusion. Regional Cancer Treatment. 1994;7:188–92.Google Scholar
  62. 62.
    Kroon HM, Coventry BJ, Giles MH, et al. Australian multicenter study of isolated limb infusion for melanoma. Ann Surg Oncol. 2016;23:1096–103.CrossRefPubMedGoogle Scholar
  63. 63.
    Coley WB. The therapeutic value of the mixed toxins of the streptococcus of erysipelas and bacillus prodigiosus in the treatment of inoperable malignant tumors. With a report of 160 cases. Am J Med Sci. 1896;112:251–81.CrossRefGoogle Scholar
  64. 64.
    Nathanson L, Schoenfeld D, Regelson W, et al. Prospective comparison of intralesional and multipuncture BCG in recurrent intradermal melanoma. Cancer. 1979;43:1630–5.CrossRefPubMedGoogle Scholar
  65. 65.
    Krown SE, Hilal EY, Pinsky CM, et al. Intralesional injection of the methanol extraction residue of bacillus Calmette-Guerin (MER) into cutaneous metastases of malignant melanoma. Cancer. 1978;42:2648–60.CrossRefPubMedGoogle Scholar
  66. 66.
    Mastrangelo MJ, Sulit HL, Prehn LM, et al. Intralesional BCG in the treatment of metastatic malignant melanoma. Cancer. 1976;37:684–92.CrossRefPubMedGoogle Scholar
  67. 67.
    Oratz R, Hauschild A, Sebastian G, et al. Intratumoral cisplatin/adrenaline injectable gel for the treatment of patients with cutaneous and soft tissue metastases of malignant melanoma. Melanoma Res. 2003;13:59–66.CrossRefPubMedGoogle Scholar
  68. 68.
    Adler A, Stein JA, Kedar E, et al. Intralesional injection of interleukin-2-expanded autologous lymphocytes in melanoma and breast cancer patients: a pilot study. J Biol Response Mod. 1984;3:491–500.PubMedGoogle Scholar
  69. 69.
    Thompson JF, Hersey P, Wachter E. Chemoablation of metastatic melanoma using intralesional rose Bengal. Melanoma Res. 2008;18:405–11.CrossRefPubMedGoogle Scholar
  70. 70.
    Andtbacka RH, Kaufman HL, Collichio F, et al. Talimogene Laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33:2780–8.CrossRefGoogle Scholar
  71. 71.
    Allen BJ, Raja C, Rizvi S, et al. Intralesional targeted alpha therapy for metastatic melanoma. Role of electrochemotherapy in the treatment of metastatic melanoma and other metastatic and primary skin tumors [Review]. Cancer Biol Ther. 2006;5:118–9.CrossRefGoogle Scholar
  72. 72.
    Byrne CM, Thompson JF, Johnston H, et al. Treatment of metastatic melanoma using electroporation therapy with bleomycin (electrochemotherapy). Melanoma Res. 2005;15:45–51.CrossRefPubMedGoogle Scholar
  73. 73.
    Campana LG, Testori A, Mozzillo N, et al. Treatment of metastatic melanoma with electrochemotherapy. J Surg Oncol. 2014;109:301–7.CrossRefPubMedGoogle Scholar
  74. 74.
    Dolinsek T, Prosen L, Cemazar M, et al. Electrochemotherapy with bleomycin is effective in BRAF mutated melanoma cells and interacts with BRAF inhibitors. Radiol Oncol. 2016;50:274–9.CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Kunte C, Letule V, Gehl J, et al. Electrochemotherapy in the treatment of metastatic malignant melanoma: a prospective cohort study by InspECT. Br J Dermatol. 2017;176(6):1475–85.CrossRefPubMedGoogle Scholar
  76. 76.
    Okino M, Mohri H. Effects of a high-voltage electrical impulse and an anticancer drug on in vivo growing tumors. Jpn J Cancer Res. 1987;78:1319–21.PubMedGoogle Scholar
  77. 77.
    Damian DL, Thompson JF. Treatment of extensive cutaneous metastatic melanoma with topical diphencyprone. J Am Acad Dermatol. 2007;56:869–71.CrossRefPubMedGoogle Scholar
  78. 78.
    Delamere G, Poirier P, Charpy A. The lymphatics: general anatomy of the Lymphatics, with special study of the Lymphatics in different parts of the body. Westminster: Archibald Constable & Co. Ltd; 1903.Google Scholar
  79. 79.
    Bartholin T. De lacteis thoracicis in homine brutisque nuperrime observatis, historia anatomica. Martzan, M: Copenhagen, Denmark; 1652.Google Scholar
  80. 80.
    Nieweg OE, Uren RF, Thompson JF. The history of sentinel lymph node biopsy. Cancer J. 2015;21:3–6.CrossRefPubMedGoogle Scholar
  81. 81.
    Virchow R. Die Krankhaften Geschwulste. Berlin, Germany: Hirschwald; 1863.Google Scholar
  82. 82.
    Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127:392–9.CrossRefPubMedGoogle Scholar
  83. 83.
    Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307–17.CrossRefPubMedGoogle Scholar
  84. 84.
    Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370:599–609.CrossRefPubMedPubMedCentralGoogle Scholar
  85. 85.
    Faries MB, Thompson JF, Cochran AJ, et al. Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. N Engl J Med. 2017;376:2211–2222.Google Scholar
  86. 86.
    Thompson JF, Uren RF, Shaw HM, et al. Location of sentinel lymph nodes in patients with cutaneous melanoma: new insights into lymphatic anatomy. J Am Coll Surg. 1999;189:195–204.CrossRefPubMedGoogle Scholar
  87. 87.
    Uren RF, Howman-Giles RB, Shaw HM, et al. Lymphoscintigraphy in high-risk melanoma of the trunk: predicting draining node groups, defining lymphatic channels and locating the sentinel node. J Nucl Med. 1993;34:1435–40.PubMedGoogle Scholar
  88. 88.
    Hill GJ 2nd, Krementz ET, Hill HZ. Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A). Cancer. 1984;53:1299–305.CrossRefPubMedGoogle Scholar
  89. 89.
    Coates AS, Segelov E. Long term response to chemotherapy in patients with visceral metastatic melanoma. Ann Oncol. 1994;5:249–51.CrossRefPubMedGoogle Scholar
  90. 90.
    Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008;26:5233–9.CrossRefPubMedPubMedCentralGoogle Scholar
  91. 91.
    Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17:2105–16.CrossRefGoogle Scholar
  92. 92.
    Atkins MB, Hsu J, Lee S, et al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the eastern cooperative oncology group. J Clin Oncol. 2008;26:5748–54.CrossRefPubMedPubMedCentralGoogle Scholar
  93. 93.
    Flaherty KT, Lee SJ, Zhao F, et al. Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. J Clin Oncol. 2013;31:373–9.CrossRefPubMedGoogle Scholar
  94. 94.
    Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363:809–19.CrossRefPubMedPubMedCentralGoogle Scholar
  95. 95.
    Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507–16.CrossRefPubMedPubMedCentralGoogle Scholar
  96. 96.
    Falchook GS, Long GV, Kurzrock R, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet. 2012;379:1893–901.CrossRefPubMedPubMedCentralGoogle Scholar
  97. 97.
    Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367:107–14.CrossRefPubMedGoogle Scholar
  98. 98.
    Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from phase II and phase III trials of Ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33:1889–94.CrossRefPubMedPubMedCentralGoogle Scholar
  99. 99.
    Lee J, Kefford R, Carlino M. PD-1 and PD-L1 inhibitors in melanoma treatment: past success, present application and future challenges. Immunotherapy. 2016;8:733–46.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • John F. Thompson
    • 1
    • 2
    • 3
    • 4
    Email author
  • Richard Kefford
    • 1
    • 5
  • Graham Stevens
    • 6
    • 7
  • Richard Scolyer
    • 1
    • 2
    • 3
  1. 1.Melanoma Institute AustraliaThe University of SydneySydneyAustralia
  2. 2.Sydney Medical SchoolThe University of SydneySydneyAustralia
  3. 3.Royal Prince Alfred HospitalCamperdownAustralia
  4. 4.Faculty of Medicine and Health SciencesMacquarie UniversityNorth RydeAustralia
  5. 5.Westmead HospitalWestmeadAustralia
  6. 6.Western Sydney University, Bathurst Clinical SchoolBathurstAustralia
  7. 7.Orange HospitalOrangeAustralia

Personalised recommendations